文献速递慢性肾脏病血液净化与透析

SGLT-2抑制剂在晚期CKD患者中的疗效与安全性:系统综述与Meta分析

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD: Systematic Review and Meta-Analysis.
PubMed 文献 · Clin J Am Soc Nephrol · 2025-03-26

该系统综述与Meta分析纳入10项3期随机对照试验,共4800例eGFR<30 ml/min/1.73 m2的晚期CKD患者,评估SGLT-2抑制剂(SGLT-2i)的疗效与安全性。结果显示,SGLT-2i在晚期CKD患者中仍降低复合肾脏结局风险(RR 0.79,95%CI 0.70-0.89),且不增加AKI、尿路感染、骨折或不良事件停药风险。

要点

  • SGLT-2i在eGFR<30 ml/min/1.73 m2患者中降低复合肾脏结局风险(RR 0.79)。
  • 晚期CKD患者使用SGLT-2i未增加AKI、尿路感染、骨折或不良事件停药。
  • 晚期CKD中SGLT-2i的降糖效应减弱,无HbA1c变化且容量不足事件更少。

核心结论

  • SGLT-2i在晚期CKD患者中保留肾脏和心血管保护作用,且未增加安全性担忧。

研究设计与样本

  • 系统综述与Meta分析,纳入10项3期随机对照试验,共4800例eGFR<30 ml/min/1.73 m2的成人患者。
  • 检索MEDLINE和Embase数据库从建库至2024年4月。
  • 主要结局为复合肾脏结局(肾功能恶化、肾衰竭、肾脏或心血管死亡)和复合心血管结局(心血管死亡或心衰住院)。
  • 采用随机效应模型估计风险比(RR),并评估基线eGFR(<30 vs ≥30 ml/min/1.73 m2)的交互效应。

主要发现

  • 在eGFR<30 ml/min/1.73 m2患者中,SGLT-2i降低主要复合肾脏结局发生率(RR 0.79;95%CI 0.70-0.89)。
  • 在eGFR≥30 ml/min/1.73 m2患者中,SGLT-2i降低主要复合肾脏结局发生率(RR 0.71;95%CI 0.64-0.79)。
  • 在eGFR<30 ml/min/1.73 m2患者中,SGLT-2i组主要心血管结局发生率数值上较低(RR 0.88;95%CI 0.71-1.10)。
  • 在eGFR≥30 ml/min/1.73 m2患者中,SGLT-2i降低复合心血管结局发生率(RR 0.77;95%CI 0.71-0.83)。
  • 晚期CKD状态与SGLT-2i对任何主要或次要结局的效应之间无交互作用,不良事件发生率两组相似。

关键数值与推荐

  • 晚期CKD定义为eGFR<30 ml/min/1.73 m2。
  • SGLT-2i在晚期CKD中降糖效应减弱,导致糖化血红蛋白无变化且容量不足事件更少。
  • SGLT-2i未增加AKI、尿路感染、骨折或不良事件导致的治疗中断发生率。

临床怎么用

  • 对于eGFR<30 ml/min/1.73 m2的晚期CKD患者,可考虑使用SGLT-2i以降低复合肾脏结局风险。
  • 使用SGLT-2i时无需过度担忧AKI、尿路感染、骨折或不良事件停药风险。
  • 晚期CKD患者使用SGLT-2i的降糖效果有限,但肾脏和心血管保护作用仍存在。

局限性

  • 原文未明确报告纳入研究的随访时长、具体药物种类及地域分布等细节。
  • 晚期CKD患者样本量有限(共4800例),可能影响部分结局的精确性。
  • 主要心血管结局在晚期CKD患者中的置信区间较宽且跨1,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

KEY POINTS: Treatment with sodium-glucose cotransporter-2 inhibitor (SGLT-2i) provides kidney and cardiovascular protection in patients with advanced CKD. The glycosuric action of SGLT-2i is attenuated in advanced CKD resulting in no change in glycated hemoglobin and fewer volume depletion events. The use of SGLT-2i did not increase the incidence of AKI, urine infections, fractures, or treatment discontinuation due to adverse events. BACKGROUND: The efficacy and safety of sodium-glucose cotransporter-2 inhibitor (SGLT-2i) in patients with advanced CKD, defined as an eGFR <30 ml/min per 1.73 m2, has not been adequately studied. METHODS: We conducted a systematic review and meta-analysis of phase 3 randomized controlled trials of SGLT-2i in adults. We searched the medical literature analysis and retrieval system online and excerpta medica database databases from inception to April 2024. The primary outcomes were composite kidney (worsening kidney function, kidney failure, and kidney or cardiovascular [CV] death) and CV (CV death or hospitalization for heart failure) outcomes. Secondary outcomes included other reported CV and kidney outcomes, eGFR slopes, mechanistic, and safety outcomes. The risk ratios (RR) were estimated using a random effects model. Interaction effects were estimated for treatment effect modification by baseline eGFR (<30 and ≥30 ml/min per 1.73 m2). RESULTS: A total of ten randomized controlled trials were included (total of 4800 patients with eGFR <30 ml/min per 1.73 m2). Participants were randomized to receive either placebo or an SGLT-2i. The use of SGLT-2i was associated with a lower incidence of the primary composite kidney outcome in patients with eGFR <30 ml/min per 1.73 m2 (RR, 0.79; 95% confidence interval [CI], 0.70 to 0.89) and ≥30 ml/min per 1.73 m2 (RR, 0.71; 95% CI, 0.64 to 0.79). The incidence of the primary CV outcome was numerically lower in the SGLT-2i arm in patients with eGFR <30 ml/min per 1.73 m2 (RR, 0.88; 95% CI, 0.71 to 1.10). In patients with eGFR ≥30 ml/min per 1.73 m2, SGLT-2i use was associated with a lower incidence of the composite CV outcome (RR, 0.77; 95% CI, 0.71 to 0.83). However, there was no interaction between advanced CKD status and the effect of SGLT-2i on any of the primary or secondary outcomes. The incidence of adverse events was similar in both arms. CONCLUSIONS: SGLT-2i retain their kidney and CV protective effect in patients with advanced CKD, with no added safety concerns.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Elenjickal EJ, Travlos CK, Luu J, et al. Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients with and without Advanced CKD: Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol. 2025. PMID: 40137838. doi:10.2215/CJN.0000000693

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。